$302 Million is the total value of Krensavage Asset Management, LLC's 14 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 7.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| UTHR | Sell | UNITED THERAPEUTICS CORP | $47,417,000 | +31.1% | 201,228 | -0.2% | 15.68% | +25.7% |
| ALKS | Sell | ALKERMES PLC | $41,651,000 | +11.2% | 1,398,159 | -1.8% | 13.77% | +6.6% |
| REGN | Sell | REGENERON PHARMACEUTICALS | $35,695,000 | -23.6% | 60,384 | -9.7% | 11.80% | -26.7% |
| EXEL | Sell | EXELIXIS INC | $31,373,000 | -9.6% | 1,506,885 | -1.5% | 10.37% | -13.3% |
| ENTA | Buy | ENANTA PHARMACEUTICALS INC | $29,533,000 | -24.4% | 624,768 | +13.8% | 9.76% | -27.5% |
| MCK | Sell | MCKESSON CORP | $27,041,000 | -28.9% | 82,894 | -33.2% | 8.94% | -31.8% |
| New | EMBECTA CORP | $25,755,000 | – | 1,017,194 | +100.0% | 8.51% | – | |
| BIIB | Buy | BIOGEN INC | $23,912,000 | +2.0% | 117,248 | +5.3% | 7.90% | -2.2% |
| TARO | Buy | TARO PHARMACEUTICAL INDUS | $20,992,000 | -14.3% | 580,524 | +2.6% | 6.94% | -17.8% |
| CAH | Buy | CARDINAL HEALTH INC | $9,348,000 | +1149.7% | 178,839 | +1254.8% | 3.09% | +1097.7% |
| EGRX | Buy | EAGLE PHARMACEUTICALS INC | $5,377,000 | -5.4% | 121,014 | +5.4% | 1.78% | -9.2% |
| KOD | Buy | KODIAK SCIENCES INC | $4,234,000 | +21.7% | 554,192 | +23.0% | 1.40% | +16.8% |
| NXTC | Buy | NEXTCURE INC | $146,000 | -2.0% | 30,999 | +1.3% | 0.05% | -5.9% |
| ASMB | Sell | ASSEMBLY BIOSCIENCES INC | $21,000 | 0.0% | 9,985 | -1.1% | 0.01% | 0.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-16
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITED THERAPEUTICS CORP | 36 | Q3 2023 | 18.1% |
| Enanta Pharmceuticals Inc | 35 | Q3 2023 | 16.7% |
| INVACARE CORP | 28 | Q3 2021 | 5.8% |
| RTI SURGICAL INC | 23 | Q2 2020 | 7.9% |
| MCKESSON CORP | 20 | Q3 2022 | 16.3% |
| BIOGEN INC | 19 | Q3 2023 | 16.0% |
| MERCK & CO. INC. | 18 | Q1 2019 | 11.1% |
| DIGIRAD CORP | 18 | Q1 2019 | 1.0% |
| REGENERON PHARMACEUTICALS | 16 | Q3 2023 | 16.1% |
| ALKERMES PLC | 16 | Q3 2023 | 14.1% |
View Krensavage Asset Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| SURGALIGN HOLDINGS, INC. | February 19, 2021 | 5,380,449 | 6.6% |
| RTI SURGICAL, INC. | February 14, 2019 | 3,852,567 | 6.1% |
| Aviragen Therapeutics, Inc. | February 15, 2018 | 2,292,058 | 5.9% |
| ENANTA PHARMACEUTICALS INC | February 15, 2017 | 883,902 | 4.6% |
| Biota Pharmaceuticals, Inc. | February 17, 2016 | 2,267,655 | 5.9% |
View Krensavage Asset Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SCHEDULE 13G | 2024-02-27 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-15 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-16 |
| 13F-HR | 2023-02-15 |
| 13F-HR | 2022-11-15 |
| 13F-HR | 2022-08-16 |
| 13F-HR | 2022-05-17 |
| 13F-HR | 2022-02-15 |
View Krensavage Asset Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.